Cobimetinib
Spécifications
934660-93-2Numéro CAS
[3,4-difluoro-2-(2-fluoro-4-iodoanilino)phenyl]-[3-hydroxy-3-[(2S)-piperidin-2-yl]azetidin-1-yl]methanoneNom IUPAC
C21H21F3IN3O2Formule chimique
531.3 g/molMasse molaire
Cobimetinib; 934660-93-2; XL518; GDC-0973; Cotellic; GDC 0973; Xl-518; XL 518; RG 7420; RG7420; ER29L26N1X; CHEBI:90851; DTXSID60239435; Methanone, (3,4-difluoro-2-((2-fluoro-4-iodophenyl)amino)phenyl)(3-hydroxy-3-((2S)-2-piperidinyl)-1-azetidinyl)-; 1-{3,4-difluoro-2-[(2-fluoro-4-iodophenyl)amino]benzoyl}-3-[(2S)-piperidin-2-yl]azetidin-3-ol; cobimetinibum; (3,4-difluoro-2-((2-fluoro-4-iodophenyl)amino)phenyl)-(3-hydroxy-3-((2S)-piperidin-2-yl)azetidin-1-yl)methanone; [3,4-difluoro-2-[(2-fluoro-4-iodophenyl)amino]phenyl]-[3-hydroxy-3-[(2S)-piperidin-2-yl]azetidin-1-yl]methanone; 1-(3,4-difluoro-2-((2-fluoro-4-iodophenyl)amino)benzoyl)-3-((2S)-piperidin-2-yl)azetidin-3-ol; Methanone, [3,4-difluoro-2-[(2-fluoro-4-iodophenyl)amino]phenyl][3-hydroxy-3-[(2S)-2-piperidinyl]-1-azetidinyl]-; RefChem:56315; MEK Inhibitor GDC-0973; DTXCID80161926; L01XE38; Cobimetinib [USAN:INN]; UNII-ER29L26N1X; MFCD22124461; [3,4-difluoro-2-(2-fluoro-4-iodoanilino)phenyl]-[3-hydroxy-3-[(2S)-piperidin-2-yl]azetidin-1-yl]methanone; CHEMBL2146883; (S)-(3,4-difluoro-2-((2-fluoro-4-iodophenyl)amino)phenyl)(3-hydroxy-3-(piperidin-2-yl)azetidin-1-yl)methanone; [3,4-difluoro-2-[(2-fluoro-4-iodophenyl)amino]phenyl][3-hydroxy-3-[(2S)-2-piperidinyl]-1-azetidinyl]methanone; C21H21F3IN3O2; RG-7420; Cobimetinib (GDC-0973, RG7420); [3,4-Bis(Fluoranyl)-2-[(2-Fluoranyl-4-Iodanyl-Phenyl)amino]phenyl]-[3-Oxidanyl-3-[(2s)-Piperidin-2-Yl]azetidin-1-Yl]methanone; [3,4-Difluoro-2-[(2-fluoro-4-iodophenyl)amino]phenyl][3-hydroxy-3-(2S)-2-piperidinyl-1-azetidinyl]methanone; [3,4-difluoro-2-(2-fluoro-4-iodo-phenylamino)-phenyl]-((s)-3-hydroxy-3-piperidin-2-yl-azetidin-1-yl)-methanone; [3,4-difluoro-2-(2-fluoro-4-iodoanilino)phenyl]{3-hydroxy-3-[(2S)-piperidin-2-yl]azetidin-1-yl}methanone; EUI; Cobimetinib Butyrate; Cobimetinib [USAN]; cometinib; [3,4-difluoro-2-[(2-fluoro-4-iodophenyl)amino]phenyl][3-hydroxy-3-[(2S)-2-piperidinyl]-1-azetidinyl]methanone; GDC 0973; XL 518; Cobimetinib; Cotellic; {3,4-Difluoro-2-[(2-fluoro-4-iodophenyl)amino]phenyl}{3-hydroxy-3-[(2S)-2-piperidinyl]-1-azetidinyl}methanone; COBIMETINIB [MI]; COBIMETINIB [INN]; Cobimetinib (USAN/INN); COBIMETINIB [WHO-DD]; SCHEMBL189565; GTPL7626; orb1223604; orb1303987; XL518;RG7420;Cobimetinib; SCHEMBL29358284; EX-A673; GDC0973; BSMCAPRUBJMWDF-KRWDZBQOSA-N; GLXC-90346; GDC0973; XL518; Cobimetinib; BDBM50391802; EBC-17143; NSC768068; NSC781257; NSC800075; s8041; AKOS025396263; Cobimetinib(GDC-0973; XL518)?; CCG-264727; CS-0521; DB05239; FD28742; NSC-768068; NSC-781257; NSC-800075; VS-0129; XL518 (GDC-0973); NCGC00346455-03; NCGC00346455-04; NCGC00346455-05; (3,4-difluoro-2-(2-fluoro-4-iodophenylamino)phenyl)(3-hydroxy-3-(piperidin-2-yl)azetidin-1-yl)methanone; BP-43634; HY-13064; SY069294; NS00072860; RO-5514041; D10405; EN300-25921151; G124084; BRD-K03390685-001-01-7; Q15708292; ((3,4-DIFLUORO-2-(2-FLUORO-4-IODOANILINO)PHENYL)(3-HYDROXY-3-((2S)-PIPERIDIN-2-YL)AZETIDIN-1-YL)METHANONE; (S)-[3,4-Difluoro-2-[(2-fluoro-4-iodophenyl)amino]phenyl][3-hydroxy-3-(2-piperidyl)-1-azetidinyl]methanone; {3,4-difluoro-2-[(2-fluoro-4-iodophenyl)amino]phenyl}{3-hydroxy-3-[(2S)-piperidin-2-yl]azetidin-1-yl}methanoneSynonymes
